Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Recruiting now · Phase 2
Conditions studied: Triple Negative Breast Cancer
In brief
Triple-negative breast cancer (TNBC) is among the most aggressive and lethal types of breast cancer, and currently available therapies have an unsatisfactory impact on patients' survival. The primary aim of this clinical trial is to evaluate efficacy in terms of Overall Response Rate (ORR) of atezolizumab plus cyclophosphamide and vinorelbine in first line patients with unresectable locally advanced or metastatic TNBC patients, previously treated with anti-programmed cell death ligand-1 (PD-L1) or anti-programmed cell death-1 (PD-1) - containing regimens, in the neoadjuvant/adjuvant setting.
Key facts
- Study ID
- NCT06690840
- Run by
- European Institute of Oncology
- People needed
- 45
- Starts
- 2025-03-06
- Expected to finish
- 2027-02-15
- Last updated by the study team
- 2026-01-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Signed Informed Consent Form
- Patients with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor 2 [HER2], estrogen receptor [ER], and progesterone receptor [PR] expression) PD-L1+ (Immune Cell >1% using Ventana SP142 assay), not amenable to surgical therapy
- Locally advanced or metastatic TNBC, who have received an anti-PD-1/PD-L1 containing regimen in the neoadjuvant/adjuvant setting
- No prior chemotherapy or targeted systemic therapy (including endocrine therapy) or immunotherapy for inoperable locally advanced or metastatic TNBC
- Tissue accessible for biopsies
- Expected survival of > 3 months
- Female or male subject ≥18 years
- Have measurable/evaluable metastatic disease (RECIST 1.1 criteria)
- Performance status 0-1 on Eastern Cooperative Oncology Group Performance Status (ECOG PS)
- Demonstrate adequate organ (kidney, liver) function
You may not qualify if…
- Patients with de novo metastatic TNBC OR those who have received 1 or more chemotherapy or targeted systemic therapy (including endocrine therapy) or immunotherapy regimens for advanced disease
- Immunodeficiency or systemic steroid therapy/immunosuppressive therapy within 7 days prior to study entry
- Known history of active Bacillus Tuberculosis (TBC)
- Hypersensitivity to anti- PD-L1 antibodies or its excipients
- Active autoimmune disease
- Known history of non-infectious pneumonitis
- Active infection requiring systemic therapy
- Known history of Human Immunodeficiency Virus (HIV)
- Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative])
- Live vaccine within 30 days
- Bone or brain metastases
Where it is running
- Fondazione IRCCS San Gerardo Dei Tintori — Monza, Monza, Italy (enrolling)
- European Institute of Oncology — Milan, Italy (enrolling)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma, Roma, Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma, Roma, Italy
- Azienda Sanitaria Locale Br — Brindisi, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.